Sveriges mest populära poddar
This Week in Pediatric Oncology
UtbildningVetenskap

TWiPO #87: Biotech Solutions for Pediatric Cancer Drug Development with Dr. Samuel Blackman

32 min•28 juni 2021

WATCH THE VIDEO WEBCAST HERE: https://youtu.be/PbNS-yFDTzA

Hosts Dr. Timothy Cripe & Dr. Brenda Weigel are joined by Dr. Samuel Blackman to discuss biotech solutions for pediatric cancer drug development. Dr. Blackman is the Co-Founder and Chief Medical Officer of Day One Biopharmaceuticals located in South San Francisco, CA. Tune in as Dr. Blackman discusses his career journey, the origins of Day One, and the challenges in pediatric cancer drug development today.

To learn more about Day One Biopharmaceuticals, go to https://dayonebio.com/.

Have any thoughts? Questions? Ideas for future topics? Email us at [email protected]. Subscribe to TWIPO to get notifications of new uploads.

Want to listen to TWIPO's past episodes? Visit www.solvingkidscancer.org/podcast

Fler avsnitt av This Week in Pediatric Oncology

Visa alla avsnitt av This Week in Pediatric Oncology
DFMO FDA Approval with Dr. Nicole Drezner
•35 min
New Focused Ultrasound Study for Progressive Diffuse Midline Glioma
•25 min
TWiPO #111: A Discussion on Oncofertility/Fertility Preservation with Dr. Seth Rotz
•27 min
TWiPO #110: Discussing the ”Gift from a Child” Program with Al Gustafson & Dr. Angela Waanders
•34 min
TWiPO #109: Discussing the Early Detection of Cancer Using Genomics with Dr. Trevor Pugh
•28 min
TWiPO #108: Hepatoblastoma: A Physician & Patient Family’s Story with Dr. Jim Geller & The Woolwines
•41 min
TWiPO #107: Discussing the International rEECur Trial for Ewing Sarcoma with Dr. Martin McCabe
•33 min
TWiPO #106: Genetic Predisposition in Childhood Cancer with Dr. Garrett Brodeur
•35 min
TWiPO #105: How to Build a Pediatric Cancer Disease Community with Ann Graham
•31 min
TWiPO #104: PEEL Therapeutics - Nanotechnology for Pediatric Cancer with Dr. Joshua Schiffman
•29 min

This Week in Pediatric Oncology med Solving Kids' Cancer finns tillgänglig på flera plattformar. Informationen på denna sida kommer från offentliga podd-flöden.